Analysts expect Insulet Corporation (NASDAQ:PODD) to report ($0.13) earnings per share for the current quarter, Zacks reports. Ten analysts have provided estimates for Insulet Corporation’s earnings, with the highest EPS estimate coming in at ($0.04) and the lowest estimate coming in at ($0.17). Insulet Corporation reported earnings per share of ($0.08) in the same quarter last year, which suggests a negative year over year growth rate of 62.5%. The business is scheduled to issue its next quarterly earnings report after the market closes on Thursday, August 3rd.
On average, analysts expect that Insulet Corporation will report full year earnings of ($0.48) per share for the current financial year, with EPS estimates ranging from ($0.59) to ($0.25). For the next financial year, analysts forecast that the company will report earnings of ($0.14) per share, with EPS estimates ranging from ($0.40) to $0.19. Zacks’ EPS calculations are an average based on a survey of research firms that follow Insulet Corporation.
Insulet Corporation (NASDAQ:PODD) last announced its earnings results on Monday, May 8th. The medical instruments supplier reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by $0.01. Insulet Corporation had a negative net margin of 6.81% and a negative return on equity of 48.46%. The firm had revenue of $101.70 million for the quarter, compared to analyst estimates of $97.73 million. During the same period in the previous year, the company earned ($0.19) EPS. Insulet Corporation’s revenue was up 25.2% compared to the same quarter last year.
Several brokerages have recently commented on PODD. B. Riley reissued a “neutral” rating and set a $44.00 price target on shares of Insulet Corporation in a research note on Tuesday, May 9th. BidaskClub lowered Insulet Corporation from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Insulet Corporation in a research note on Saturday, July 22nd. Jefferies Group LLC decreased their price target on Insulet Corporation from $53.00 to $48.00 and set a “buy” rating on the stock in a research note on Wednesday, May 10th. Finally, Zacks Investment Research lowered Insulet Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, July 20th. Eight research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Insulet Corporation presently has an average rating of “Buy” and an average price target of $48.15.
In other Insulet Corporation news, Director Jessica Hopfield purchased 2,580 shares of the business’s stock in a transaction on Thursday, May 11th. The stock was bought at an average cost of $38.68 per share, for a total transaction of $99,794.40. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Bradley A. Thomas purchased 3,000 shares of the business’s stock in a transaction on Thursday, May 11th. The stock was acquired at an average price of $38.69 per share, with a total value of $116,070.00. The disclosure for this purchase can be found here. Insiders acquired a total of 8,080 shares of company stock valued at $317,339 over the last quarter. 2.60% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Strs Ohio increased its position in shares of Insulet Corporation by 73.9% in the first quarter. Strs Ohio now owns 4,000 shares of the medical instruments supplier’s stock valued at $172,000 after buying an additional 1,700 shares during the period. Teacher Retirement System of Texas acquired a new position in shares of Insulet Corporation during the first quarter valued at $201,000. Diversified Trust Co acquired a new position in shares of Insulet Corporation during the second quarter valued at $205,000. Ameritas Investment Partners Inc. acquired a new position in shares of Insulet Corporation during the first quarter valued at $215,000. Finally, Fiduciary Trust Co. acquired a new position in shares of Insulet Corporation during the first quarter valued at $226,000.
ILLEGAL ACTIVITY NOTICE: “Brokerages Expect Insulet Corporation (NASDAQ:PODD) to Post -$0.13 Earnings Per Share” was reported by BNB Daily and is the sole property of of BNB Daily. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.baseball-news-blog.com/2017/08/19/brokerages-expect-insulet-corporation-nasdaqpodd-to-post-0-13-earnings-per-share-updated-updated.html.
Shares of Insulet Corporation (NASDAQ PODD) traded down 1.25% during trading on Thursday, hitting $49.68. The company’s stock had a trading volume of 290,497 shares. Insulet Corporation has a one year low of $30.69 and a one year high of $53.90. The stock has a market cap of $2.88 billion, a PE ratio of 92.00 and a beta of 1.55. The company has a 50-day moving average price of $49.83 and a 200-day moving average price of $44.58.
About Insulet Corporation
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.